Cellular Intelligence strikes deal with Novo Nordisk to advance Parkinson’s cell therapy
'This cell therapy Parkinson's program is truly innovative and exemplifies the powerful convergence of exciting academic discovery with the uncompromising quality of a global pharmaceutical leader.'
Assessment
A small Israeli biotech has secured a partnership with one of the world's largest drugmakers, signaling growing confidence in cell-based approaches to Parkinson's disease. The deal validates the scientific platform and provides financial runway for early-stage trials. The key question is whether this therapy can overcome the manufacturing and delivery hurdles that have stalled similar programs.